Immune system cells recruited by cancers to help them grow and spread could be ‘re-educated’ to attack the tumours instead of aiding them, Cancer Research UK scientists announced at the National Cancer Research Institute (NCRI) Conference in Birmingham today (Wednesday).
Interrupting a particular chemical pathway in macrophages – the immune system cells ‘hi-jacked’ by the cancer – was found to turn them back into cancer killers, capable of attacking the tumour directly and encouraging the rest of the immune system to do the same.
The treatment also significantly reduced the rate of tumour growth in mice with ovarian cancer – an important step in the development of a treatment for human cancer patients.
The findings of the research were presented by Dr Thorsten Hagemann and Prof Frances Balkwill from the Institute of Cancer, Barts and the London, Queen Mary’s School of Medicine and Dentistry.
Lead researcher Dr Hagemann said: “Macrophages that are supposed to fight infections typically end up helping cancers by releasing chemical messages that promote tumour growth.
“In fact, 50 per cent or more of a typical cancer will be made up of ‘normal’ body cells, hi-jacked by the cancer to aid its survival and growth.
“But re-educating the macrophages turned them into effective cancer killers. It also encouraged the rest of the immune system to start acting against the tumour.”
Macrophages are known to release chemical messages that activate the protein NF-?B in cells, stopping cell death and promoting cell growth and spread.
But the researchers found that by modifying the chemical signalling pathways in macrophages, they could inhibit the function of NF-?B, stopping it from promoting tumour growth.
When these modified macrophages were exposed to ovarian cancer cells, the macrophages produced nitric oxide – a toxin – which resulted in the cancer cells committing suicide.
The modification also resulted in the macrophages signalling other immune system cells to begin attacking the cancer. It caused an anti-tumour effect in the immune system as a whole.
When the modified macrophages were injected into mice with established ovarian cancer, tumour growth was found to be significantly reduced, suggesting that the technique could one day be used to treat cancer in humans.
The research was jointly funded by Cancer Research UK and an intra-European Marie Curie Fellowship.
Dr Lilian Clark, Cancer Research UK’s executive director of science operations and funding, said: “Getting the immune system to attack the tumour itself is a hugely promising approach in the development of new cancer treatments.
“Such therapies could be used to strengthen existing courses of treatment, working along side chemotherapy, radiotherapy and surgery, or as targeted alternatives to these more conventional treatments without the unpleasant side-effects.”
For media enquiries please contact the press office on 020 7061 8300, or the out-of-hours duty press officer on 07050 264 059.
Cancer Research UK
Together with its partners and supporters, Cancer Research UK’s vision is to beat cancer.
- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
For further information about Cancer Research UK’s work or to find out how to support the charity, please call 020 7009 8820 or visit our homepage.
About the NCRI Cancer Conference
The National Cancer Research Institute (NCRI) Cancer Conference is the UK’s premier forum for disseminating advances across all aspects of cancer research.
AstraZeneca is the gold sponsor for the NCRI Cancer Conference 2007.
About the NCRI
The National Cancer Research Institute (NCRI) was established in April 2001. It is a partnership between government, the voluntary sector and the private sector, with the primary mission of maximising patient benefit that accrues from cancer research in the UK through coordination of effort and joint planning towards an integrated national strategy for cancer research.
The NCRI consists of: The Association of British Pharmaceutical Industry (ABPI); The Association for International Cancer Research; The Biotechnology and Biological Sciences Research Council; Breakthrough Breast Cancer; Breast Cancer Campaign; Cancer Research UK; Department of Health; Economic and Social Research Council; Leukaemia Research Fund; Ludwig Institute for Cancer Research; Macmillan Cancer Support; Marie Curie Cancer Care; The Medical Research Council; Northern Ireland Health and Personal Social Services Research & Development Office; Roy Castle Lung Cancer Foundation; Scottish Executive Health Department; Tenovus; Wales Office of Research and Development for Health & Social Care; Wellcome Trust; and Yorkshire Cancer Research.